Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
S1929
Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker
- NCT04334941 ↗
- Active, not recruiting
- National Cancer Institute (NCI)
- Deep
We haven't built an HCP commentary report on S1929 (atezolizumab and talazoparib in Extensive Stage Lung Small Cell Carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on S1929 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 34 | |
| YouTube | 7 | |
| Podcasts | 1 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Extensive Stage Lung Small Cell Carcinoma
- Interventions
- Atezolizumab; Biopsy Procedure; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Talazoparib
- Arms
- Arm I (atezolizumab) · Active comparator
- Arm II (atezolizumab, talazoparib) · Experimental
- Enrollment
- 103
- Primary outcomes
- Progression free survival
- Sponsor
- National Cancer Institute (NCI)
- Start
- Jul 20, 2020
- Primary completion
- Nov 30, 2025
- Results posted
- No
- Registry record
- NCT04334941 · updated Jun 5, 2026